Abstract--The human genome encodes nine different adrenoceptor genes. These are grouped into three families, namely, the a 1 -, a 2 -, and b-adrenoceptors, with three family members each. Adrenoceptors are expressed by most cell types of the human body and are primary targets of the catecholamines epinephrine and norepinephrine that are released from the sympathetic nervous system during its activation. Upon catecholamine binding, adrenoceptors change conformation, couple to and activate G proteins, and thereby initiate various intracellular signaling cascades. As the primary receivers and transducers of sympathetic activation, adrenoceptors have a central role in human physiology and disease and are important targets for widely used drugs. All nine adrenoceptor subtypes display substantial genetic variation, both in their coding sequence as well as in adjacent regions. Despite the fact that some of the adrenoceptor variants range among the most frequently studied genetic variants assessed in pharmacogenetics to date, their functional relevance remains ill defined in many cases. A substantial fraction of the associations reported from early candidate gene approaches have not subsequently been confirmed in different cohorts or in genome-wide association studies, which have increasingly been conducted in recent years. This review aims to provide a comprehensive overview of all adrenoceptor variants that have reproducibly been detected in the larger genome sequencing efforts. We evaluate these variants with respect to the modulation of receptor function and expression and discuss their role in physiology and disease.
I. Introduction
Adrenoceptors are central mediators in the sympathetic nervous system, adjusting organ functions to maintain whole-body homeostasis under resting conditions and triggering the body's fight-or-flight response, i.e., the ability to react to acute stress. Stress conditions induce the release of epinephrine from the adrenal medulla into the blood stream and of norepinephrine from sympathetic nerve endings. Both catecholamines bind to and activate the three subfamilies of adrenoceptors: a 1 -adrenoceptors (ADRA1, subdivided into ADRA1A, ADRA1B, and ADRA1D), a 2 -adrenoceptors (ADRA2, subdivided into ADRA2A, ADRA2B, and ADRA2C), and b-adrenoceptors (ADRB, subdivided into ADRB1, ADRB2, and ADRB3) (Bylund et al., 1994; Hieble et al., 1995) . In addition, adrenoceptors serve to recognize catecholamines that are released as neurotransmitters within the central nervous system. Sequencing of the respective genomic loci in human populations from diverse ethnical backgrounds revealed that the genes encoding adrenoceptor subtypes are polymorphic, meaning that the genomic sequence in coding and regulatory regions differs among individuals at certain residues (Kirstein and Insel, 2004) . In general, any change in the amino acid sequence may confer local steric or charge incompatibilities and thereby result in altered structure or function of these receptors. Variations in the N terminus, the extracellular loops, or the ligand binding pocket itself may possibly alter the accessibility of the ligand binding pocket and thereby change the affinity of ligands as well as their potency to induce intracellular signaling. Some ligands at adrenoceptors are able to activate multiple cellular signaling pathways (e.g., via different G proteins or arrestin) (Reiter et al., 2012) , allowing for further impact of variation in adrenoceptors. Certain adrenoceptor ligands were shown to preferentially activate a specific signaling pathway compared to other ligands at the same receptor, a concept that has been termed functional selectivity or biased signaling (Kenakin, 2013) . Variations in the intracellular parts of adrenoceptor proteins in turn may be expected to preferentially alter the interaction with G proteins or other interacting proteins. Genetic variation outside the coding sequence in the 59-and 39-flanking regions may act in a cis-regulatory manner and determine adrenoceptor gene expression.
A. Adrenoceptor Structure
Adrenoceptors are class A G protein-coupled receptors (GPCRs). They consist of seven transmembrane (TM)-spanning a-helical domains, an extracellular region ABBREVIATIONS: ADRA, a-adrenoceptor; ADRB, b-adrenoceptor; CHO, Chinese hamster ovary; COPD, chronic obstructive pulmonary disease; del, deletion; GPCR, G protein-coupled receptor; GRK, G protein-coupled receptor kinase; GWAS, genome-wide association study; HEK-293, human embryonic kidney 293; IP 3 , inositol triphosphate; MAPK, mitogen-activated protein kinase; SNP, single-nucleotide polymorphism; TM, transmembrane; UTR, untranslated region.
Adrenoceptor Polymorphic Variants 599 (N terminus, three extracellular loops), and an intracellular region (three intracellular loops, C terminus) (Fig. 1) . Their low abundance, structural flexibility, and instability in detergent solution have long hindered resolution of the structure of GPCRs, apart from that of rhodopsin. However, recent advances in protein engineering and crystallography techniques Warne et al., 2008; Steyaert and Kobilka, 2011) resulted in the elucidation of the structure of several GPCRs, including the turkey b 1 -adrenoceptor (Warne et al., 2008 (Warne et al., , 2011 (Warne et al., , 2012 and the human b 2 -adrenoceptor (Rasmussen et al., , 2011a ; Rosenbaum et al., 2007 Rosenbaum et al., , 2011 . More recently, these studies also partially revealed the structural changes that occur upon activation and resolved the interaction interface with G proteins (Rasmussen et al., 2011b) and arrestins (Shukla et al., 2013) . Ligand docking initiates conformational rearrangements within the helices, constricting the binding pocket and thereby the release of the ligand (Ring et al., 2013) . The largest conformational changes in the prototypical b 2 -adrenoceptor are an a-helical extension of TM5 and an outward movement at the cytoplasmic end of TM6 (Rasmussen et al., 2011b) . The intracellular region of adrenoceptors interacts with G proteins and additional proteins that serve scaffolding and signaling functions. Adrenoceptors are highly dynamic proteins that may adopt multiple distinct conformations depending on the type of ligand bound, the associated signaling proteins, and the membrane environment (Deupi and Kobilka, 2010) . These different conformations and their dynamic alteration were assessed using techniques such as nuclear magnetic resonance spectroscopy (Nygaard et al., 2013) , fluorescence resonance energy transfer (Lohse et al., 2012) , or molecular dynamics simulations (Dror et al., 2011) . Some of these techniques were also applied to the analysis of adrenoceptor variation (Ahles and Engelhardt, 2009) . concentrations. a 2 -Adrenoceptors are G i coupled and inhibit AC. b 1 -, b 2 -, and b 3 -adrenoceptors couple to G s , activate AC, and promote the generation of cAMP. cAMP activates PKA regulating the activity of multiple cellular proteins. b 2 -Adrenoceptors are reported to undergo a PKA-dependent switch from G s to G i coupling (Daaka et al., 1997) . b 3 -Adrenoceptors also activate nitric oxide synthase via G i coupling. Please note that the individual adrenoceptors differ considerably with regard to the length of their non-TM regions. These differences are not represented within the schematic receptor drawings. (B) Gbg-dependent and G protein-independent signaling of adrenoceptors. Once activated, adrenoceptors are phosphorylated by PKA and PKC and by GRKs leading to b-arrestin recruitment. Arrestin prevents activation of G proteins and promotes receptor desensitization and internalization. Both arrestin and Gbg mediate the activation of MAPKs. AC, adenylyl cyclase; b-Arr, b-arrestin; DAG, diacylglycerol; EPI, epinephrine; NE, norepinephrine; PIP 2 , phosphoinositol-bis-phosphate; PKA, protein kinase A; PKC, protein kinase C; PLC, phospholipase C.
B. Signaling through Adrenoceptors
Each subfamily of adrenoceptors preferentially couples to a different type of G protein. Catecholamine binding to a 1 -adrenoceptors activates G q , whose a-subunit then activates phospholipase C, which converts phosphatidylinositol-4,5-bisphosphate to the second messengers inositol triphosphate (IP 3 ) and diacylglycerol. a 2 -Adrenoceptors couple to G i with G i a inhibiting adenylyl cyclase activity and thus intracellular cAMP formation. Activated b-adrenoceptors primarily couple to the stimulatory G protein G s and promote cAMP formation. Figure 1A illustrates the canonical G protein coupling of the three adrenoceptor families, albeit coupling to alternative G proteins was reported for several of their members. For example, G i coupling has been shown for both the ADRB2 and the ADRB3 (Soeder et al., 1999; Xiao, 2001) .
G protein activation results in its dissociation and thus the release of the bg-subunit that may promote so-called alternative signaling by itself, such as the activation of mitogen-activated protein kinases (MAPKs) and ion channel regulation. ADRA1A-mediated activation of MAPK and phosphoinositide 3 kinase were both shown to depend on G i (Snabaitis et al., 2005; Vettel et al., 2012) .
Furthermore, GPCRs, including adrenoceptors, have been demonstrated to signal in a G protein-independent manner through their interaction with several regulatory proteins (such as G protein-coupled receptor kinases [GRKs] and b-arrestins) and scaffolding proteins (such as PDZ domain-containing proteins; Lefkowitz, 2007) . Most of this G protein-independent signaling is shown to involve MAPKs (Fig. 1B) .
C. Physiology of Adrenoceptors
The majority of cells in the human body express one or several of the nine adrenoceptor subtypes at their surface (see Brunton et al., 2011) . One particular receptor often dominates in certain cells in effector organs of the sympathetic nervous system or in the central nervous system. Likewise, the equipment of different cell types with G proteins and downstream signaling molecules is different. This heterogeneity allows for diverse responses of tissues and organs to catecholamines released from the sympathetic nervous system or within the central nervous system. These nonsympathetic sources of catecholamines are not specifically mentioned in the following but meant to be included.
For example, sympathetic activation and the resulting release of epinephrine and norepinephrine may induce both contraction and relaxation of vascular smooth muscle cells depending on their preferentially expressed adrenoceptor subtype. Vascular smooth muscle cells in the skin contract upon exposure to epinephrine, an effect that is dominated by a 1 -adrenoceptor signaling. By contrast, the predominance of b 2 -adrenoceptors in vascular smooth muscle cells within skeletal muscle arteries mediates their relaxation in response to epinephrine (Brunton et al., 2011) . Together, the concerted sympathetic activation of adrenoceptors elicits the fightor-flight-response, which has evolved during evolution as a critical regulatory mechanism to adapt multiple physiologic functions in a coordinated way. Among other effects, the fight-or-flight response increases cardiac output, elevates blood pressure, and thereby allows for adequate organ perfusion and oxygen supply during times of increased demand. At the same time, smooth muscular organs such as the bladder or the uterus relax (Kirstein and Insel, 2004) . Inadequate activation of the fight-or-flight-response was elucidated to serve a critical role as a disease-aggravating factor in several civilizationrelated disorders such as high blood pressure and coronary and myocardial disease (Lymperopoulos et al., 2013) . If genetic variation of adrenoceptors indeed affects their expression or function, then one may reasonably presume consequences not only for organ physiology but also for disease development. However, even if a given variant is relevant for the expression level or function of an adrenoceptor, its association with a phenotype may only become apparent under conditions of continuous receptor activation. For most cases, such a scenario would typically necessitate long-term activation of the sympathetic nervous system, a condition that is likely not met in many of the diseases studied in this regard.
D. Adrenoceptors as Drug Targets
Adrenoceptors are important targets for widely used classes of therapeutic drugs. Competitive antagonists at b-adrenoceptors (also termed b-blockers) belong to the most frequently used GPCR-targeting drugs and are particularly important in cardiovascular medicine, where they are applied in the treatment of hypertension, coronary artery disease, tachyarrhythmia, and chronic heart failure (Lymperopoulos et al., 2013) . Agonists at b 1 -adrenoceptors are used to provide inotropic support in acute cardiac failure, and b 2 -agonists such as salbutamol are a standard regimen in asthma. Antagonists at a 1 -adrenoceptors are used as antihypertensive agents and for symptomatic treatment of benign prostate hyperplasia, whereas agonists at a 1 -and/or a 2 -adrenoceptors are widely used for nasal decongestion.
For several of these adrenoceptor-targeting drugs, pronounced interindividual variation with regard to treatment responses has been reported. In addition to other factors, genetic heterogeneity of adrenoceptor genes among patients is suggested as a possible underlying cause for the variation of therapeutic efficacy when using these agents (Rosskopf and Michel, 2008) .
Here, we review the current evidence regarding the effect of adrenoceptor variation on receptor function and expression and on its role in physiology and disease. Approximately 4000 different variations in the genes encoding adrenoceptors (excluding the promoter regions) are reported to date, including single nucleotide variations as well as insertion/deletion mutants. Single nucleotide variations have traditionally been classified with regard to their relative frequency in the general population (i.e., their allelic frequency) into mutations (allelic frequency ,1%) and single-nucleotide polymorphisms (SNPs) (allelic frequency $1%). If the exchange of one respective nucleotide in the coding region does not change the amino acid sequence, the variation is called synonymous. Despite resulting in an unchanged protein sequence, such variations have the potential to affect expression levels of the host gene in a cis-regulatory manner (Cartegni et al., 2002) . By contrast, nonsynonymous variations result in an amino acid change and thus may alter protein function by changing its primary structure.
The first nonsynonymous variant in a GPCR was described in 1993 for the b 2 -adrenoceptor (Reihsaus et al., 1993) , followed by reports of amino acid variation for all a 1 -, a 2 -, and b-adrenoceptor subtypes. This review largely focuses on variation in coding regions, yet a linkage to noncoding variants may become relevant for certain phenotypes (see Sections IV and VII on ADRA2A and ADRB3). Methods for identifying variants have changed over time and include single-strand conformational techniques, allele-specific polymerase chain reaction, allele-specific oligonucleotide hybridization, single base extension and polymerase chain reaction product restriction digestion, and increasingly direct sequencing (Reihsaus et al., 1993; Hall et al., 1995; Turki et al., 1995; Mason et al., 1999) .
The variations were commonly indicated as follows (exemplified in brackets for amino acids of a ADRB1 variant, Gly389Arg): wild type (i.e., Gly), position of variant amino acid (i.e., 389), mutant (i.e., Arg). While traditionally the first cloned sequence was termed the wild-type sequence, this variant was not necessarily the more common variant. A good example is position 389 in human b 1 -adrenoceptor, in which the Arg variant is indeed far more frequent than the Gly variant that was cloned first (Frielle et al., 1987) . Throughout this article, we adopt the following nomenclature: nucleotide position, major allele, and minor allele for description at the genomic level (i.e., c.1165C.G); and, accordingly, "major" amino acid, position, and "minor" amino acid for description at the protein level (i.e., p.Arg389Gly). In-frame deletions are described using "del" after indication of the first and last deleted nucleotide/amino acid. Regarding variants in the 39-and 59-untranslated regions (UTRs), the nucleotide 59 of the ATG-translation initiation codon is denoted as 21, and the nucleotide 39 of the translation stop codon is denoted as *1. This nomenclature is consistent with the guidelines proposed by the Human Genome Variation Society (www.hgvs.org/mutnomen/).
Because of the rapid progress in sequencing technologies, whole exomes and genomes of larger cohorts can be read faster than ever. It thus became possible to reassess the frequency of variants, which had often been reported from genotyping of only few individuals, in cohorts of .6000 individuals (both European Americans and African Americans). Some of these data are currently publicly available through the Exome Variant Server (National Institutes of Health National Heart, Lung, and Blood Institute Exome Sequencing Project, evs.gs.washington.edu/EVS) or the 1000 Genomes Project browser (browser.1000genomes. org). The latter two sources provided the basis for the selection of the adrenoceptor variations covered in this review. The availability of whole genome sequences of larger cohorts (as opposed to preselected SNP data sets) also led to a revision of the above-mentioned classification of genetic variation into SNPs and mutations. Variations occurring at a minor allelic frequency of .5% are now classified as common. Those variations occurring in 0.5-5% of individuals are classified as low frequency, and those with frequencies of ,0.5% and ,0.05% as rare and very rare, respectively (Abecasis et al., 2012) . Singletons, by definition, are only found on one allele of one individual in a particular study. Naturally, singletons have a higher likelihood of representing sequencing artifacts, and are not covered in this review. The terms genetic variation and variant used throughout this review comprise both single nucleotide variations and deletion mutants.
This review puts special emphasis on genetic variants for which either structural, functional, or clinical data have been reported (see Table 1 for an overview of all functionally characterized adrenoceptor variants; see Supplemental Table 1 for the reference SNP identification numbers of all other variants mentioned). To address the exceedingly large numbers of clinical studies, we set a threshold of $100 individuals analyzed for candidate gene approaches and $1000 individuals for genome-wide association studies (GWAS). This threshold, however, was not applied for drug response studies performed ex vivo or in healthy volunteers, because these are likely subjected to less confounding parameters than association studies performed in patients. Wherever possible, we rank the studies according to the number of individuals studied within the respective tables.
reported to increase inotropy and to promote hypertrophy, albeit these effects may be more prominent in rodents compared with humans O'Connell et al., 2014) . a 1 -Adrenoceptor signaling induces the contraction of smooth muscle cells, thereby controlling blood pressure, bladder, and prostate tone and pupil width. Furthermore, a 1 -adrenoceptors are abundant postsynaptic receptors in the brain, where they stimulate neurotransmitter release (Piascik and Perez, 2001 ). The three subtypes of a 1 -adrenoceptors (ADRA1A, ADRA1B, and ADRA1D) predominantly couple to the heterotrimeric G q /G 11 protein. Receptor activation increases intracellular calcium concentration through IP 3 -mediated release from internal stores and by capacitive influx via membrane calcium channels. In addition, activation of MAP kinase signaling has been reported, at least in part mediated by G i bg (Snabaitis et al., 2005) .
Crystal structures of a 1 -adrenoceptor subtypes are lacking to date; thus, any structure-based assumptions are currently restricted to homology modeling with known GPCR structures such as those of the b 2 -adrenoceptor.To date, 15 variants are identified in the coding region of the a 1A -adrenoceptor (Fig. 2) , along with 6 in the a 1B -adrenoceptor (Fig. 3) and 14 in the a 1D -adrenoceptor (Fig. 4) . Several nonsynonymous variants in the a 1A -adrenoceptor have been functionally investigated, with c.1039C.T (p.Arg347Cys) receiving the highest attention. By contrast, regarding the coding region of the ADRA1B, only synonymous variants have been studied (Büscher et al., 1999; McCaffery et al., 2002) and none of the variants in the ADRA1D displayed in Fig. 4 has been functionally investigated to date.
A. Receptor Pharmacology
The ADRA1A gene has 14 transcripts (splice variants), 10 of which are predicted to allow for the synthesis of functional proteins. The other four transcripts are presumed to undergo nonsense-mediated decay or to result in aberrant protein. Six of the ADRA1A splice variants have a C-terminal tail that includes the variation c.1039C.T. At the respective position in the translated protein, Arg is frequently replaced by Cys (allelic frequencies of 45% Arg and 55% Cys in European Americans and 74% Arg and 26% Cys in African Americans; note that this site was also previously named Arg492Cys). Cys347 is predicted to generate a potential additional palmitoylation site; however, because of its close proximity to the primary palmitoylation site at Cys345, it remains to be tested whether Cys347 indeed provides for additional (Shibata et al., 1996; Lei et al., 2005) . Essentially, the current evidence indicates that this frequent variation does not affect signaling through the a 1A -adrenoceptor (Table 2) . Five additional repeatedly reported variants of the a 1A -adrenoceptor were subjected to pharmacological analysis in vitro with regard to ligand binding affinity, agonist-induced IP 3 production, and desensitization (Lei et al., 2005) : c.460T.G (p.Ser154Ala) and c.497G. A (p.Arg166Lys) in TM4, c.599T.G (p.Ile200Ser) in TM5, as well as c.739G.A (p.Gly247Arg) in intracellular loop 3 and c.1395A.T (p.Glu465Asp) in the C-terminal tail present in the two full-length splice variants of the a 1A -adrenoceptor (see Fig. 2 for their location within the a 1A -adrenoceptor). Table 2 summarizes the results of the functional analyses.
Interestingly, the very rare Arg247 variant of the a 1A -adrenoceptor (prevalence ,0.05%) increased proliferation of rat-1 fibroblasts by 2-fold compared with the Gly247 variant. Enhanced cell proliferation in the Arg247 variant was subsequently shown to result from a 1A -adrenoceptor-mediated transactivation of the endothelial growth factor receptor, which boosted MAPK signaling. This effect was dependent on b-arrestin 1, but did not necessitate agonist or G protein activation. The authors suggested that p.Gly247Arg may alter the conformation of the third intracellular loop and thus facilitate its interaction with b-arrestin 1 (Oganesian et al., 2011) .
B. Role in Human Physiology and Disease
Several candidate gene approaches have been undertaken to study the association of the frequent variation p.Arg347Cys with phenotypes in humans in those organs in which signaling through the a 1A -adrenoceptor is functionally important. The results of association studies on p.Arg347Cys with regard to blood pressure regulation and heart rate were variable and not (Table 3) . However, two studies on a Chinese population reported a significant association of Arg347 with lower antihypertensive effects of the calcium channel blocker nifedipine and the angiotensin receptor antagonist irbesartan (Jiang et al., 2005; Zhang et al., 2009) . Regarding the role of a 1A -adrenoceptors in the brain, association studies on schizophrenia and schizophreniaassociated metabolic abnormalities were both negative (Bolonna et al., 2000; Cheng et al., 2012) . Finally, no association could be determined with regard to the onset of benign prostatic hyperplasia (Shibata et al., 1996) . In line with the negative overall outcome of candidate gene approaches, the ADRA1A, ADRA1B, and ADRA1D genomic regions did not show a significant association with any trait in the large GWAS reported to date (also see Table 4 for an overview of large GWAS).
C. Response to Therapeutic Drugs
Studies investigating the short-term response to specific receptor agonists and antagonists should be subject to fewer confounding factors than those of complex disease phenotypes and can be expected to show less variation if conducted in a well defined cohort. Antagonists at the a 1 -adrenoceptors are applied as antihypertensives and are first-line drugs for symptomatic treatment of benign prostatic hyperplasia. In addition, several antipsychotics possess high affinity to a 1 -adrenoceptors, which is suggested to contribute to their antipsychotic efficacy (Leucht et al., 2013) . However, p.Arg347Cys in the a 1A -adrenoceptor was not related to alterations in response to antipsychotics drugs (Bolonna et al., 2000) or to urinary incontinence as a side effect of the antipsychotic clozapine (Hsu et al., 2000) . Likewise, treatment efficacy of a 1 -adrenoceptor antagonists for benign prostatic hyperplasia did not Fig. 3 . Nonsynonymous variations in the human a 1B -adrenoceptor. ADRA1B gene locus (chromosome 5: 159,343,790-159,399,551, forward strand) and localization of the variations in the coding region (exons 1 and 2) and adjacent regions. Variation data were extracted as described in Fig. 2 . bp, base pair; EL, extracellular loop; IL, intracellular loop; kb, kilobase; MAF, minor allelic frequency. Fig. 4 . Nonsynonymous variations in the human a 1D -adrenoceptor. ADRA1D gene locus (chromosome 20: 4,201,329-4,229,721, reverse strand) and localization of the variations in the coding region (exons 1 and 2) and adjacent regions. For extraction of variation data, see Fig. 2 . bp, base pair; EL, extracellular loop; IL, intracellular loop; kb, kilobase; MAF, minor allelic frequency.
Adrenoceptor Polymorphic Variants depend on p.Arg347Cys (Mochtar et al., 2006) . Finally, this variant did not alter phenylephrine-mediated vasoconstriction in healthy subjects .
Taken together, the current evidence does not clearly suggest functional differences for the variants present in the a 1A -, a 1B -, and a 1D -adrenoceptor genes. Interesting observations made for the a 1A -adrenoceptor, such as the increased MAPK activation and cell proliferation by the Arg247 variant and limited responses to blood pressurelowering agents reported for the Arg347 variant, await their confirmation in ex vivo systems and in independent cohorts.
IV. Variants of a 2A -, a 2B -, and a 2C -Adrenoceptors All three a 2 -subtypes (ADRA2A, ADRA2B, and ADRA2C) couple to inhibitory G i proteins (Fig. 1) . a 2 -Adrenoceptors regulate multiple physiologic processes, including neurotransmitter release, platelet aggregation, blood pressure, insulin secretion, and lipolysis (Knaus et al., 2007) . No crystal structure of a a 2 -adrenoceptor has been reported thus far.
All common coding variants (i.e., variants with an allele frequency of .5%, which are depicted in red in the corresponding figures) are located within the third Jiang et al. (2005) intracellular loop of the respective ADRA2 genes, a region that is critical for G protein coupling and kinase-mediated regulation of GPCRs (Chen et al., 1993) . To date, one coding variant is functionally characterized for each of the three a 2 -adrenoceptor subtypes: c.798C.G (p.Asn266Lys) in ADRA2A, c.901_909del (p.Glu301_Glu303del) in ADRA2B, and c.964_975del (p.Gly322_Pro325del) in ADRA2C (see Figs. 5-7 for an overview on the location of these and other variants in the a 2 -adrenoceptors).
A. Variants of the a 2A -Adrenoceptor 1. Receptor Pharmacology. The Asn to Lys substitution at position 266 in the a 2A -adrenoceptor (numbered 251 in earlier publications) is rare in Caucasians and has an allelic frequency of approximately 2-4% in African Americans (Small et al., 2000a) . Upon overexpression in Chinese hamster ovary (CHO) and COS-7 cells, the two ADRA2A variants showed similar ligand binding properties (Table 5) . Interestingly, the authors report that agonist-induced G protein activation [measured by 59-O-(3-thiotriphosphate) binding] was approximately 40% higher in cells transfected with the Lys266 receptor variant compared with Asn266. Consistent with this, activation of the Lys266 variant led to stronger activation of MAPK and inositol phosphate signaling and inhibition of adenylyl cyclase activity (Small et al., 2000a) . Together, these data suggest a gain of function for the minor Lys266 variant. In addition, a single study described and characterized variants in the noncoding regions of the ADRA2A gene. These are clustered with p.Arg266Lys within complex haplotypes and are reported to affect receptor expression (Small et al., 2006) .
2. Role in Human Physiology and Disease. p.Asn266Lys was investigated for an association with essential hypertension, but this small study did not provide support for a role in blood pressure regulation (Small et al., 2000a) .
However, an association with insulin secretion and the risk of type 2 diabetes was reported for a variation located in the 39 UTR, which is expected to alter the expression of ADRA2A: c.*427G.A (rs553668; minor Adrenoceptor Polymorphic Variants allelic frequency, 29%). The minor allele was associated with impaired insulin secretion in two Scandinavian cohorts of 935 and 4935 individuals, respectively (Rosengren et al., 2010) , as well as in 1345 Italians (Bo et al., 2012) . Rosengren et al. (2010) reported that carriers of the risk allele (A) display higher a 2A -adrenoceptor expression. The molecular mechanism resulting in altered receptor expression remains to be elucidated. It might involve the disruption of a micro-RNA-binding site, yet the site is rather poorly conserved and has not been studied to date with regard to microRNA-dependent regulation.
Insulin secretion from pancreatic islets is inhibited by the activation of a 2A -adrenoceptors in b cells. Increased expression of the a 2A -adrenoceptor would thus promote impaired insulin release, which is a pathogenic mechanism of type 2 diabetes. Indeed, the minor allele went along with a significantly increased risk of type 2 diabetes in a study of Scandinavian individuals (2830 and 3740 participants with and without diabetes, respectively; Rosengren et al., 2010) , in a study of lean Chinese Han individuals (1042 patients with type 2 diabetes and 1052 control subjects; Li et al., 2012) , as well as in a meta-analysis (Talmud et al., 2011 ). An impairment of lipid and glucose metabolism in hypertensive patients was previously observed in an early study that determined a DraI restriction fragment length polymorphism, which corresponds to rs553668 . Furthermore, rs553668 was associated with increased blood pressure (Sõber et al., 2009 ), yet Michel et al. (1999) did not report such an association.
Another variant in the noncoding region of the ADRA2A gene, located 1252 nucleotides upstream of the start codon ATG, was associated with psychiatric disorders in few candidate gene studies: 10:g.112836503C.G (rs1800544; Fig. 5 ). Namely, this variant was reported to determine the treatment efficacy of antipsychotics (Park et al., 2006; Lee et al., 2009 ) and that of the sympathomimetic methylphenidate in the treatment of attention deficit hyperactivity disorder in children (Polanczyk et al., 2007; Cheon et al., 2009) but not in adults (Contini et al., 2011) .
With the advent and availability of high-throughput genomic technologies, unbiased studies and GWAS have become the gold standard in assessing the impact of genetic variation on human phenotypic variation (Motsinger-Reif et al., 2013) . However, neither this 59-upstream variant nor p.Asn266Lys or the 39-UTR variation c.*427G.A were associated with any trait in large GWAS. However, GWAS recently reported associations of two variants downstream of the ADRA2A with agonist-induced platelet aggregation (g.112909105G.A, rs869244; Johnson et al., 2010) and fasting glucose (g.113042093T.G, rs10885122; Dupuis et al., 2010) . Because these variants are located approximately 70 or 203 kilobases downstream of the ADRA2A gene locus, the underlying mechanism remains to be determined and might also be independent of the a 2A -adrenoceptor.
Studies on ADRA2A variants with regard to the response to therapeutic drugs have not been reported to date.
B. Variants of the a 2B -Adrenoceptor 1. Receptor Pharmacology. Three deletion variants have been identified in ADRA2B. All of them are relatively common, occur in-frame, and map to a small region within the third intracellular loop (Fig. 6 ). This region is rich in acidic residues (aspartate and glutamate) and is thought to establish the milieu for agonist-promoted phosphorylation by GRKs and desensitization of the receptor (Chen et al., 1993) . One of the deletion variants (p.Glu301_Glu303del) was subjected to functional analysis in several cell lines in vitro. The authors report that transfection with the deletion variant reduced GRK-mediated phosphorylation and desensitization in COS-7 or CHO cells (Small et al., 2001) , in neuroblastoma/glioma hybrid NG108 cells (Salim et al., 2009) , and in the chromaffin PC12 cell line (Nguyen et al., 2011) (Table 5) .
2. Role in Human Physiology and Disease. On the basis of the reports on hyperfunctionality of p.Glu301_Glu303del (Small et al., 2001; Salim et al., 2009; Nguyen et al., 2011) , several candidate gene studies have tested for the association of the p.Glu301_Glu303del variation of the a 2B -adrenoceptor with cardiovascular disorders. The four largest studies on this variant all delineated an increased risk for sudden cardiac death and coronary events (Table 6 ). In addition, an association of p.Glu301_Glu303del with the risk or early onset of diabetes was previously reported (Siitonen et al., 2004; Heinonen et al., 2005; Papazoglou et al., 2006) (Table 6 ). However, hopes that one cause of these diseases may be found in genetic variation of the a 2B -adrenoceptor were diminished when subsequent large GWAS could not provide confirmation (Samani et al., 2007; Erdmann et al., 2009 Erdmann et al., , 2011 Reilly et al., 2011; Schunkert et al., 2011; Lu et al., 2012) (Table 4) .
3. Response to Therapeutic Drugs. Similar to endogenous catecholamines, synthetic a 2 -agonists activate presynaptic a 2 -adrenoceptors. Activation of presynaptic a 2 -adrenoceptors inhibits neurotransmitter release (e.g., norepinephrine release from sympathetic nerve endings and acetylcholine release from parasympathetic nerve endings). The a 2 -agonists in clinical use do not possess relevant subtype selectivity. They are useful as sedative, hypnotic, and anesthetic-sparing drugs to lower sympathetic tone during cardiac surgery and prevent postoperative cardiovascular complications. a-Agonists are furthermore frequently used as over-the-counter nasal decongestants. This effect is likely mediated via postsynaptic receptors (ADRA1 and ADRA2) (Gilsbach and Hein, 2012) .
Effects of p.Glu301_Glu303del in the a 2B -adrenoceptor on the therapeutic efficacy of a 2 -agonists have been Adrenoceptor Polymorphic Variants studied in small, standardized cohorts of healthy volunteers but not in larger cohorts of patients. Here, no association with agonist-induced vasoconstriction and blood pressure elevation was observed in the majority of studies (Table 7) .
C. Variants of the a 2C -Adrenoceptor 1. Receptor Pharmacology. Similar to the a 2B -adrenoceptor, the human a 2C -adrenoceptor contains a common in-frame deletion variant in its third intracellular loop (Fig. 7) . Because of the deletion of four amino acids (Gly-Ala-Gly-Pro, p.Gly322_Pro325del), this variant lacks an acidic motif in a region that is assumed to be important for G protein coupling. This location is suggestive of altered functionality of the deletion variant, yet studies in cell lines reported divergent findings. Whereas Small et al. (2000b) reported significantly less epinephrine-stimulated adenylyl cyclase inhibition and MAPK and inositol signaling for the deletion variant in CHO cells, Montgomery and Bylund (2010) found that there were no effects of this variation on agonist-stimulated adenylyl cyclase activity in human embryonic kidney 293 (HEK-293) cells. Variations in receptor subcellular localization, dimerization, and downstream signaling components as well as the presence of additional variants in downstream factors are proposed to account for these discrepancies, yet they are awaiting further experimental investigation.
2. Role in Human Physiology and Disease. Studies on the p.Gly322_Pro325del variation in the a 2C -adrenoceptor have mostly focused on heart failure (Gilsbach and Hein, 2012) (Table 6 ). The first analysis reported a marked increase in the risk for heart failure for homozygous carriers of the deletion variant (Small et al., 2002) . A further increase in risk was reported for individuals that were also homozygous for the (hyperfunctional) Arg389 variant of the b 1 -adrenoceptor (Small et al., 2002) .The authors suggested that this combination of receptor variants might lead to enhanced presynaptic norepinephrine release (controlled through a putatively less functional a 2C -adrenoceptor variant) coupled with enhanced postsynaptic signaling (through the hyperfunctional Arg389 variant of the b 1 -adrenoceptor; see Section V). It should be noted, however, that the number of homozygotes for both p.Gly322_Pro325del in the a 2C -adrenoceptor and Arg389 in the b 1 -adrenoceptor in this original report was low (2 of 84 control subjects and 15 of 78 patients The asterisk indicates that a composition bias is described for amino acids 294-311, because this region is rich in acidic residues (aspartate and glutamate). bp, base pair; CDS, coding region sequence; EL, extracellular loop; IL, intracellular loop; kb, kilobase; MAF, minor allelic frequency.
with heart failure) and that subsequent studies did not corroborate this association. Three independent studies on different ethnic cohorts including African Americans (the population in which this association was originally reported) reported no association of the p.Gly322_Pro325del alone or in combination with the Arg389 variant of the b 1 -adrenoceptor in heart failure (Table 8) (Nonen et al., 2005; Metra et al., 2006; Canham et al., 2007) . Likewise, p.Gly322_Pro325del was not associated with essential hypertension (Table 6 ) . Taken together, the current body of evidence, including candidate gene studies and GWAS, does not suggest an association of the ADRA2C variation p.Gly322_Pro325del with cardiovascular disease (Table 4) .
3. Response to Therapeutic Drugs. Similar to ADRA2A and ADRA2B, the impact of genetic variation in a 2C -adrenoceptors has not been intensely studied with regard to the efficacy of therapeutic drugs. A single study in healthy volunteers reported increased norepinephrine spillover and higher heart rates caused by the a 2 -antagonist yohimbine in carriers of the Gly322_Pro325del variant of the a 2C -adrenoceptor compared with controls (Neumeister et al., 2005) .
In summary, the current body of evidence suggests that at least two a 2 -adrenoceptor variants might be functionally relevant. The risk allele of rs553668 in the 39-UTR of the a 2A -adrenoceptor leads to enhanced receptor expression and is reproducibly shown to be associated with diabetes. Likewise, the deletion variant p.Glu301_Glu303del in the coding region of the a 2B -adrenoceptor alters receptor function and is associated with impaired glucose tolerance/diabetes and cardiovascular disease in multiple studies. Recent GWAS on platelet aggregation and fasting glucose reported two additional variants located in the 39-downstream region of the a 2A -adrenoceptor, with a possible (but not proven) cis-regulatory effect on the receptor gene, which might regulate expression of the ADRA2A. (Maqbool et al., 1999; Mason et al., 1999; Tesson et al., 1999) with frequencies of approximately 27% in Caucasians and Asians and 42% in African Americans. Because of linkage disequilibrium between codons 49 and 389, the haplotype Gly49-Gly389 is extremely rare.
A. Receptor Structure
The first crystal structure of the turkey b 1 -adrenoceptor with the antagonist cyanopindolol bound was reported in 2008 (Warne et al., 2008) . The receptor protein was modified for expression and crystallization purposes without disturbing its functionality . Six thermostabilizing mutations were introduced (Arg68Ser, Met90Val, Tyr227Ala, Ala282Leu, Phe327Ala, Phe338Met) that shifted the receptor equilibrium toward the inactive state. N and C termini were truncated, the major part of intracellular loop 3 was deleted, and the C-terminal palmitoylation site Cys358 was removed by mutation to Ala358. A structure of the fully active state has not been obtained, because the thermostabilized receptor protein tends toward an inactive state and the structure was obtained in the absence of a G protein, the latter being most likely indispensable to stabilize the active conformation (Rasmussen et al., 2011b) . In addition, the adrenoceptor structures resolved to date could not resolve the N-terminal parts (including p.Ser49Gly within the b 1 -adrenoceptor), which is suggested to be due to the lack of clearly structured parts and the resulting spatial flexibility of the N terminus (Venkatakrishnan et al., 2013 ). An additional hurdle for future attempts to resolve the structure of the N terminus of the b 1 -adrenoceptor is its poor interspecies conservation, which would necessitate studies with the human protein.
Detailed structural data have been obtained from a truncated version of the turkey b 1 -adrenoceptor that retained the region surrounding position 355 (which corresponds to position 389 in humans). Position 355 in the turkey b 1 -adrenoceptor is located in helix 8, which is formed by a stretch of amino acids starting from the distal seventh TM-spanning domain to the membraneanchoring palmitoylated cysteine (Fig. 8B) . The structure of the antagonist-bound turkey receptor suggests that Arg355 forms a hydrogen bond with Thr69 in helix 1. Because the interspecies variation in this region is low, these data also appear to be valid for the human b 1 -adrenoceptor. Given this finding, it is postulated that Arg389, but not Gly389, in the human b 1 -adrenoceptor specifically interacts with this threonine residue in TM1. This interaction would stabilize the receptor and lower the energy barrier toward an active state (Warne et al., 2012) , thereby suggesting a structural basis for hyperfunctionality of the Arg389 variant. This hypothesis still awaits experimental testing.
B. Receptor Pharmacology
p.Ser49Gly and p.Arg389Gly were characterized in vitro regarding their ligand binding properties, agonist-induced conformational changes, and signaling efficacy. Ligand binding and agonist-stimulated adenylyl cyclase activity were found to be very similar for the two variants at position 49 when moderately overexpressed in Chinese hamster fibroblasts or HEK-293 cells . With higher (supraphysiological) expression levels (.0.5 pmol/mg protein in HEK-293 cells), the Gly49 variant displayed enhanced affinity for agonists and antagonists, as well as constitutive activity with increased basal and agonist-stimulated adenylyl cyclase activity and agonist-induced receptor downregulation Rathz et al., 2002) (Table 9 ). This finding, however, was recently not reproduced in HEK-293 cells expressing the variant at different densities (Baker et al., 2013) and also not in an ex vivo analysis of agonist-induced contractility of cardiac tissue (Molenaar et al., 2002; Sarsero et al., 2003) . Of note, the in vitro studies conducted in cell lines on p.Ser49Gly were carried out on the Gly389 background, despite the fact that the haplotype Gly49-Gly389 does not seem to exist (or, at least, is extremely rare).
Likewise, the variation p.Arg389Gly has been intensely investigated in vitro (Table 9 ). Upon overexpression in cell lines, the Arg389 variant-expressing cells displayed higher basal and agonist-induced adenylyl cyclase-mediated cAMP formation (Mason et al., 1999; Joseph et al., 2004) . This was paralleled by enhanced coupling to G s and high-affinity ligand binding solely in the absence of GTP (Mason et al., 1999) . The latter was regarded as indirect evidence that position 389 was located in the putative G protein coupling region of the receptor protein, albeit current evidence from the b 2 -adrenoceptor-G s structure locates G protein coupling to intracellular loop 3 (Rasmussen et al., 2011b; Venkatakrishnan et al., 2013) . In addition, alternative methodology using fluorescence resonance energy transfer to monitor G protein activation found no difference for p.Arg389Gly regarding activation of G s . However, the latter study reported an increased basal beating frequency of primary Arg389-overexpressing cardiomyocytes compared with Gly389-overexpressing cells (Rochais et al., 2007) . The authors found differential conformational changes of the Arg389 variant toward specific b-adrenoceptor antagonists and suggested that position 389 influences conformation of the receptor protein itself (Rochais et al., 2007) .
In agreement with a higher efficacy, the Arg389 variant exhibited greater agonist-promoted desensitization than the Gly389 variant Adrenoceptor Polymorphic Variants this notion at least for Gly49/Arg389 with higher cAMP formation, receptor downregulation, and relative desensitization of cAMP formation (Sandilands et al., 2004) . Upon cardiomyocyte-specific transgenic overexpression of the human b 1 -adrenoceptor variants Arg389/Gly389 in mice, increased basal and dobutamine-induced contractility levels were reported for the Arg389 variant compared with the Gly389 variant, with enhanced desensitization of the Arg389 variant in older animals (Mialet Perez et al., 2003) . Finally, ex vivo studies in heart tissue examining the native receptors did not uniformly support the hyperfunctional role of Arg389 compared with Gly389 (Table 9 ). The different disease conditions of the patients are a possible reason for these discrepancies; thus, the hyperfunctionality of Arg389 may only become apparent when contraction force is severely impaired (Molenaar et al., 2002; Sandilands et al., 2003) .
C. Role in Human Physiology and Disease
Stimulation of cardiac b 1 -adrenoceptors is believed to be the strongest endogenous mechanism to increase cardiac output and it is this adrenoceptor subtype that functionally dominates in the myocardium. Its cardiac role and its tight control of renin release also explain the central role of b 1 -adrenoceptors in the control of blood pressure.
To test whether the variation p.Arg389Gly influences cardiac responsiveness in vivo, several groups investigated dynamic exercise-evoked increases in heart rate and contractility and plasma renin activity in healthy subjects. These studies (analyzing up to 890 individuals) showed no genotype-dependent differences Xie et al., 2001; Liu et al., 2003; Sofowora et al., 2003; Leineweber et al., 2006a; Nieminen et al., 2006) .
The numerous clinical studies on the relevance of the variants p.Ser49Gly and p.Arg389Gly in b 1 -adrenoceptors have primarily focused on cardiovascular diseases, namely hypertension and heart failure. Using a candidate gene approach, several studies have addressed a potential association of these variants with hypertension. Although the results of the smaller studies are highly divergent, three larger cohorts revealed that Fig. 2 . The asterisk indicates that although G (Gly389 codon GGA) is the minor allele at position 389, it is referred to as the wild-type allele and C (Arg389 codon CGA) is referred to as the variant allele in most databases, because the first cloned b 1 -adrenoceptor contained Gly389 (Dixon et al., 1986) . The pound sign (#) indicates variation in the second nucleotide of codon for 389: G.T. Starting from the wild-type GGA (Gly), this results in codon GTA (Val). However, starting from the more common Arg389 variant (codon CGA), exchange of the second nucleotide leads to codon CTA (Leu). The latter is not taken into account in the majority of SNP databases. (B) Localization of the functionally studied coding-region variations p.Ser49Gly and p.Gly389Arg in the ADRB1 protein. bp, base pair; CDS, coding region sequence; EL, extracellular loop; IL, intracellular loop; kb, kilobase; MAF, minor allelic frequency.
Arg389 was consistently associated with the risk for hypertension (Table 10 ).
The largest GWAS on blood pressure to date (including .120,000 European individuals) found a variation approximately 22 kilobases upstream of the ADRB1 gene to be significantly associated with mean arterial pressure (g.115781527C.T, rs2782980; Fig. 8 ) (Wain et al., 2011) . This suggests an implication of the ADRB1 genomic region in blood pressure regulation, yet requires further analysis. The p.Arg389Gly variation, however, did not emerge in any of the 17 GWAS, which assessed blood pressure or hypertension in a cohort size larger than 1000 individuals (Table 4) . This negative outcome of the GWAS casts some doubt on the interpretation of the respective candidate gene studies. In contrast to studies on hypertension, the number of candidate gene studies and GWAS addressing heart failure were significantly smaller. In summary, they do not indicate the ADRB1 locus to be consistently associated with heart failure (Tables 4 and 11 ). A recent genome-wide analysis found that the p.Arg389Gly variant of the b 1 -adrenoceptor was significantly associated with birth weight in 69,308 Europeans (Horikoshi et al., 2013) . Again, the mechanistic basis for this association remains speculative at this point and requires further analysis.
D. Response to Therapeutic Drugs
All data published to date on the effect of b 1 -adrenoceptor variation with regard to the response to b-agonists and b-antagonists refer to candidate gene studies with no genome-wide data available. Infusion of the b-agonist dobutamine into healthy individuals that were homozygous for Arg389 induced significantly larger increases in contractility, heart rate, or plasma renin activity than in Gly389 carriers (La Rosée et al., 2004; Bruck et al., 2005b) . Accumulating evidence shows that p.Arg389Gly affects the response to b-adrenoceptor antagonists (i.e., b-blockers) that are widely used therapeutic agents in cardiovascular disease, including hypertension and heart failure. In healthy individuals, the effect of b-blockers has been studied under conditions of increased heart rate and blood pressure (by exercise or dobutamine infusion). Whereas basal and maximal hemodynamics did not differ between Arg389 and Gly389 homozygotes, the relative decrease of these parameters evoked by b-blockers was greater for Arg389 in four of five studies (Table 12 ). This suggests a stronger response of the Arg389 variant to b-blockers under normal conditions (i.e., in healthy individuals).
Most studies in patients have focused on heart failure and investigated the influence of b 1 -adrenoceptor variation on the response to b-blockers. Several large trials in heart failure had previously established a strong, mortality-lowering effect of bisprolol, metoprolol, and carvedilol (Cardiac Insufficiency Bisoprolol Study Investigators and Committees, 1994; MERIT-HF Study Group, 1999; Poole-Wilson et al., 2003) . Consequently, several smaller studies (i.e., patient cohort size ,1000) reported a higher efficacy of various b-blockers for the Gly49 and Arg389 variants. Moreover, two metaanalyses of studies in patients with heart failure comprising 504 and 1561 individuals, respectively, indicated a significantly greater improvement of left ventricular ejection fraction for individuals who received b-blockers and were homozygous for Arg389 compared with treated Gly389 carriers (Muthumala et al., 2008; . Additional support for the clinical relevance of the variation at position 389 of the b 1 -adrenoceptor comes from the b-Blocker Evaluation of Survival Trial and its substudies, which reported a higher clinical efficacy for bucindolol in Arg389 carriers with heart failure O'Connor et al., 2012; Aleong et al., 2013) (Table 13) .
In summary, the available data strongly suggest functional relevance of polymorphic variation in the 
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Ahles and Engelhardt ADRB1 gene. With some confidence, the more common Arg389 variant can be regarded as hyperfunctional compared with the Gly389 variant. Arg389 has rather consistently been associated with a stronger response to b-agonists and b-blocking agents in healthy volunteers and in patients, respectively. By contrast, an association of Arg389 with various diseases has yielded mixed results. The mechanistic basis underlying the variant in the 59 upstream region (g.115781527C.T) determining blood pressure remains to be established, including its relation to the b 1 -adrenoceptor.
VI. Variants of the b 2 -Adrenoceptor
Thirteen nonsynonymous variants have been identified in the coding region of human b 2 -adrenoceptor (ADRB2; Fig. 9 ). The two N-terminally located variants c.46G.A (p.Gly16Arg) and c.79G.C (p.Gln27Glu) as well as c.491C.T (p.Thr164Ile) in TM4 are shown to affect the functional properties of the receptor both in vitro and in vivo. Additional variants are located within the 59-UTR upstream of the start codon (McGraw et al., 1998) . Of these, c.-47T.C appears to be functionally relevant. This variant is located within a short open reading frame, called the b-upstream peptide or the 59-leader cistron of the b 2 -adrenoceptor, and was formerly termed Arg19Cys. Strong linkage disequilibrium between codons 16 and 27 favors a combination of Arg16 with Gln27 (Dewar et al., 1998) .
A. Receptor Structure
Despite remarkable success in the crystallization of the human b 2 -adrenoceptor protein bound to agonists (Rosenbaum et al., 2011; Rasmussen et al., 2011a,b; Ring et al., 2013) or antagonists Rasmussen et al., 2007; Rosenbaum et al., 2007) , the Pacanowski et al. (2008a) ACS, acute coronary syndrome; AMI, acute myocardial infarction; CAD, coronary artery disease; CHF, chronic heart failure; DCM, dilated cardiomyopathy; HF, heart failure; HT, hypertensive; ICM, idiopathic cardiomyopathy; LV, left ventricular; MI, myocardial infarction; NT, normotensive.
Adrenoceptor Polymorphic Variants structural impact of the two most common variants of the b 2 -adrenoceptor (both located in the N terminus) remains obscure. The N-terminal part was not visible in the structures or it was intentionally cleaved upfront and the T4 lysozyme was fused to the truncated N terminus (Rasmussen et al., 2011a) . Agonist binding affects the conformation of the receptor's extracellular regions, suggesting that amino acid variations in this region might affect receptor activation despite not being directly involved in ligand binding (Bokoch et al., 2010) .
Position 164 is located within the upper part of TM4 (Fig. 9B) . The substitution of threonine by isoleucine converts a polar to a hydrophobic residue. Based on the structure of the b 1 -adrenoceptor, Warne et al. (2011) suggested that this could affect the interaction between helices 4 and 5 and thereby affect the probability of transition into the activated state.
B. Receptor Pharmacology
The b 2 -adrenoceptor variants p.Gly16Arg, p.Gln27Glu, and p.Thr164Ile as well as c.-47T.C in the 59-UTR have been evaluated in vitro upon overexpression in heterologous cell systems. c.-47T.C in the b-upstream peptide affects b 2 -adrenoceptor expression at a translational level in transfected COS-7 cells (Scott et al., 1999) and in human airway smooth muscle cells (McGraw et al., (2003) HR, heart rate; MAP, mean arterial pressure; PRA, plasma renin activity; SBP, systolic blood pressure. AF, atrial fibrillation; BEST, b-Blocker Evaluation of Survival Trial; BP, blood pressure; CABG, coronary artery bypass graft; CAD, coronary artery disease; CHF, chronic heart failure; CR/XL, controlled release/extended release; DBP, diastolic blood pressure; DCM, dilated cardiomyopathy; HFREF, heart failure with reduced left ventricular ejection fraction; HR, heart rate; HT, hypertensive; LVEF, left ventricular ejection fraction; MERIT-HF, Metoprolol CR/XL Randomised Intervention Trial in Congestive Heart Failure; SBP, systolic blood pressure. 618 1998), but not in lymphocytes (Lipworth et al., 2002) (Table 14) .
1. Functional Effects of Variation in the N Terminus of the b 2 -Adrenoceptor. The impact of the polymorphic loci in the extracellular N terminus, p.Gly16Arg, and p.Gln27Glu was first studied in membrane preparations from Chinese hamster fibroblasts that were transfected with expression constructs for the ADRB2 variants. Neither ligand binding nor adenylyl cyclase activity was altered between genotypes (Green et al., 1994) . By contrast, upon overexpression in HEK-293 cells and short-term stimulation with epinephrine, the Gly16 variants (Gly16/Gln27 and Gly16/Glu27) of the b 2 -adrenoceptor displayed hyperfunctionality compared with the Arg16 variant (Arg16/Gln27) with regard to cAMP formation. This hyperfunctionality of the Gly16 variants was attributed to the speed of receptor activation since conformational changes occurred faster compared with the hypofunctional Arg16 variant. These differential changes in b 2 -adrenoceptor activation depended on phosphorylation of the receptor by GRKs (Ahles et al., 2011) . Further in vitro analysis showed a faster interaction with b-arrestin2 (Ahles et al., 2011) , suggesting a basis for the enhanced desensitization, and stronger downregulation for the Gly16 variant was reported (Green et al., 1994) . In combination with Arg16, Glu27 appeared to be resistant against agonist-promoted downregulation (Green et al., 1994) . This haplotype combination studied in vitro, however, is extremely rare in humans.
It should be noted that several studies, which investigated cAMP formation in isolated, nontransfected human cells (examining endogenous N-terminal b 2 -adrenoceptor variants), had discrepant results. These studies investigated cAMP solely after long-term receptor stimulation (i.e., .24 hours, a time frame involving substantial receptor desensitization) but did not elucidate potential differences of the individual receptor variants before desensitization had occurred (Aziz et al., 1998; Lipworth et al., 1999; Bruck et al., 2003a) . Table 14 summarizes these ex vivo studies and further analyses of agonist-promoted downregulation. (chromosome 5: 148,206,156-148,208,196, forward strand) and localization of the variations in the coding region and adjacent regions. Variation data were extracted as described in Fig. 2. (B) Localization of the functionally studied coding-region variations p.Gly16Arg, p.Glu27Gln, and p.Trp164Ile in the ADRB2 protein and c.-47T.C in the b-upstream peptide. bp, base pair; BUP, b-upstream peptide; CDS, coding region sequence; EL, extracellular loop; IL, intracellular loop; kb, kilobase; MAF, minor allelic frequency.
Adrenoceptor Polymorphic Variants 2. Functional Effects of the b 2 -Adrenoceptor Variant p.Thr164Ile in Helix 4. Interestingly, signaling defects were observed with the less common Ile164 b 2 -adrenoceptor in vitro. This variant exhibited a 3-to 4-fold lower affinity for isoproterenol and catecholamines than Thr164 b 2 -adrenoceptors and a markedly decreased agonist-receptor-G s interaction (Green et al., 1993) . Consequently, basal and agonist-stimulated adenylyl cyclase activities were also decreased upon overexpression both in cell systems and in transgenic mice (Turki et al., 1996) , suggesting a loss of function of p.Thr164Ile. In humans, Ile164 occurs with a low frequency (approximately 2% in Caucasians) and nearly almost in a heterozygous state, which makes it difficult to analyze its impact in nontransfected cell systems ex vivo. Here, the potency of b-agonists to induce either lipolysis in adipocytes or inhibition of IgE-mediated histamine release in human lung mast cells was lower in Ile164 carriers (Hoffstedt et al., 2001; Kay et al., 2003 Kay et al., , 2007 (Table 14) . This correlated with the in vitro efficacy of this particular variant, yet basal and maximal agonist responses were not affected.
C. Role in Human Physiology and Disease 1. Vasodilation and Hypertension. Activation of b 2 -adrenoceptors is a potent vasodilatory mechanism. Therefore, genetic variants that alter receptor function and regulation can be assumed to affect b 2 -adrenoceptormediated vasoregulation and possibly blood pressure.
Studies in healthy individuals that were exposed to mental stress or handgrip exercise did not show genotype-dependent differences with regard to the extent of vasodilation (Eisenach et al., 2004 (Eisenach et al., , 2005 Trombetta et al., 2005) . When evaluating a possible association of b 2 -adrenoceptor variants with the risk for hypertension, the strong linkage disequilibrium between codons 16 and 27 has to be considered: This permits only three of four haplotypes (Arg16/Gln27, Gly16/Gln27, and Gly16/Glu27).
The results of the studies that examined the impact of the b 2 -adrenoceptor variants p.Gly16Arg and p.Gln27Glu on vasodilation, blood pressure regulation, and risk for hypertension are very divergent, with the majority of the largest trials (with approximately 1500-66,000 individuals involved; Kato et al., 2001; Herrmann et al., 2002; Sethi et al., 2005; Thomsen et al., 2012a) showing no association of both variants with blood pressure or hypertension (Table 15) .
Because of the low allelic frequency of the c.491C.T (p.Thr164Ile) variant (and thus the rareness of homozygotes), a large number of participants in cohorts would be needed to improve the statistical power. Studies involving ,1000 individuals generally found no association of this variant with blood pressure or hypertension. By contrast, the two largest studies reported to date detected an association with increased blood pressure in female Ile164 carriers (Table 15) (Sethi et al., 2005; Thomsen et al., 2012a) . However, none of the variations of the ADRB2 locus displayed significant association in the seven larger GWAS reported to date regarding hypertension (Table 4) . Whether subgroup analysis in female participants would yield different results remains to be analyzed.
2. Cardiac Function and Failure. The b 2 -subtype accounts for approximately 30% of the total b-adrenoceptors in the healthy myocardium, with a relative increase in cardiac disease as b 1 -adrenoceptor levels decrease (Lymperopoulos et al., 2013) . Several candidate gene studies have analyzed the three most frequent b 2 -adrenoceptor variants with regard to the incidence and progression of heart failure. As illustrated in Table 16 , the results do not favor a strong impact of b 2 -adrenoceptor genetic variation. In addition, none of the GWAS reported to date yielded a significant association of the ADRB2 locus with cardiac disease (Table 4) (Samani et al., 2007; Erdmann et al., 2009 Erdmann et al., , 2011 Reilly et al., 2011; Schunkert et al., 2011; Lu et al., 2012) .
3. Asthma and Chronic Obstructive Pulmonary Disease. Activation of pulmonary b 2 -adrenoceptors induces strong relaxation of bronchial smooth muscle. Consequently, b 2 -adrenoceptor agonists have become an important part of asthma management, where they are used as bronchodilatory agents (British Thoracic Society, 2009) .
A considerable number of candidate gene studies have investigated the association of p.Gly16Arg, p.Gln27Glu, and p.Thr164Ile variants with asthma and chronic obstructive pulmonary disease (COPD) ( Table 17 ). The largest of these studies (.60,000 individuals) was recently published and yielded a (relatively weak) association of the Ile variant at position 164 with reduced lung function and increased risk of COPD in the general population, albeit no association of the variants at positions 16 and 27 with reduced lung function, asthma, or COPD was reported (Thomsen et al., 2012b) . In contrast with the latter large candidate gene study, none of the 18 large (n . 1000) GWAS in this focus reported a significant association of any variant in b 2 -adrenoceptors (Table 4) . Together, this suggests that there is no major impact of genetic variation in the b 2 -adrenoceptor on asthma or COPD progression and severity.
4. Preterm Labor and Preterm Birth. b 2 -Adrenoceptors are likewise expressed in smooth muscle cells of the myometrium and their activation inhibits uterine contraction. A potential association of b 2 -adrenoceptor variants with preterm birth has been addressed in few, relatively small studies. As summarized in Table 18 , the results are inconsistent and do not favor a major impact of b 2 -adrenoceptor genetic variation at positions 16 and 27 to the risk of preterm delivery. Data are also scarce and not unequivocal for the progress of regular labor at term (measured as a function of cervical dilatation; see Table 18 ).
D. Response to Therapeutic Drugs 1. Response to Agonists. The impact of the variants p.Gly16Arg and p.Gln27Glu on b-agonist-induced vasodilation has been investigated in healthy volunteers (Table 19) . Depending on the application mode (local or systemic infusion), divergent effects have been observed. Local infusion of either isoproterenol or terbutaline elicited stronger vasodilatory effects in Adrenoceptor Polymorphic Variants probands homozygous for Gly16 in three of four studies, which is in good agreement with the hyperfunctionality of the Gly16 variant reported in vitro (Ahles et al., 2011) . By contrast, systemic infusion resulted in larger vasodilation in individuals homozygous for the Arg16 variant than in Gly16 homozygotes (Gratze et al., 1999; Hoit et al., 2000; Snapir et al., 2003a) . The reason for this discrepancy is currently not understood but may involve effects on heart rate, blood pressure, and the consecutive activation of various compensatory mechanisms that typically occur after systemic stimulation of b 1 -and b 2 -adrenoceptors. Thomsen et al. (2012a) 622 Ahles and Engelhardt The response of Ile164 carriers to b 2 -agonists was investigated in healthy volunteers Bruck et al., 2003b) and in patients with congestive cardiomyopathy (Barbato et al., 2007) . In both groups, cardiac responses to infusion of the b 2 -agonist terbutaline were weaker in Ile164 carriers compared with noncarriers, supporting data obtained in vitro (Table 19) .
Moreover, patients carrying the Arg16 b 2 -adrenoceptor showed a better response to short-term administration of short-acting antiasthmatic b 2 -agonists (albuterol, terbutaline) than those carrying Gly16. Studies on treatment efficacy with long-acting b 2 -agonists showed inconsistent results (Table 20 ), suggesting that Arg16 may only provide benefit in short-term treatment. Together, these interesting findings may explain why patients suffering from asthma and other obstructive pulmonary diseases exhibit individually diverse responses to b 2 -agonists. By contrast, no impact of p.Gln27Glu was observed with regard to b 2 -agonist treatment outcome in patients with asthma (Table 20) .
Agonists at b 2 -adrenceptors are also frequently used as short-term uterine relaxing (i.e., tocolytic) agents to treat preterm labor despite limited evidence as to their overall clinical benefit (Simhan and Caritis, 2007) . One small candidate gene study investigated the influence of b 2 -adrenoceptor variation on the clinical efficacy of tocolytic therapy with the b 2 -agonist hexoprenaline and reported a (nonsignificant) trend toward later delivery in Arg16 homozygotes (Landau et al., 2005) .
2. Response to Antagonists. Current data concerning the responses to b-blockers do not support an implication of b 2 -adrenoceptor variants p.Gly16Arg and p.Gln27Glu, because the majority of studies Groote et al. (2005) ACS, acute coronary syndrome; CABG, coronary artery bypass graft; CHF, coronary heart disease; DCM, dilated cardiomyopathy; HTx, heart transplantation; MI, myocardial infarction.
Adrenoceptor Polymorphic Variants comprising .100 patients report no difference in treatment efficacy (Table 20) .
In summary, the N-terminal genetic variants p.Gly16Arg and p.Gln27Glu exert rather minor functional effects, with the Gly16 variant reported as hyperfunctional in some (but not all) studies performed in vitro. In vivo, this variant has been linked to higher blood pressure, yet the underlying mechanism is unclear. The relatively infrequent p.Thr164Ile variation might determine b 2 -adrenoceptor function to a more relevant degree. The Ile164 variant is hypofunctional in various in vitro systems and ex vivo. It also appears to predispose to hypertension and is apparently less efficacious when studied in healthy volunteers and thus might be classified as a loss-of-function variant.
VII. Variants of the b 3 -Adrenoceptor
The b 3 -adrenoceptor (ADRB3) is most prominently expressed in adipose tissue, gall bladder, and parts of the colon (Krief et al., 1993; Berkowitz et al., 1995) . The b 3 -adrenoceptor was originally assigned a role in promoting lipolysis and thermogenesis (Emorine et al., 1989; Arch, 2008) , yet this function is most likely restricted to rodents (Michel et al., 2010) . Multiple other roles for the b 3 -adrenoceptor were subsequently elucidated, including activation of nitric oxide synthase in cardiomyocytes, relaxation of the urinary bladder (Michel et al., 2010) , and most recently release of hematopoietic stem cells and progenitor cells from the bone marrow in myocardial infarction (Dutta et al., 2012) . The b 3 -subtype was the last of the b-adrenoceptors to Ahles and Engelhardt be cloned and has been studied considerably less compared with the b 1 -and the b 2 -subtype. To date, there is no crystal structure of a b 3 -adrenoceptor (although a high similarity to the b 1 -and b 2 -adrenoceptors seems likely) and therapeutic drugs specifically targeting the b 3 -adrenoceptor were only recently approved. The Exome Variant Server currently lists 10 variants that have reproducibly been reported within the coding sequence of the ADRB3 gene (Fig. 10) , with two variants occurring at a frequency .0.5%: c.491C.T (p.Trp64Arg) and c.1075C.G (p.Arg353Cys). Two further variations in the coding region were described in Chinese individuals: c.493T.C (p.Ser165Pro) and c.769C.T (p.Ser257Pro) (Huang et al., 2013a) . Of these, the variation at position 64, which resides at the intracellular end of TM1, has attracted the most scientific interest.
A. Receptor Pharmacology
The effect of the b 3 -adrenoceptor variants containing either tryptophan or arginine at position 64 has been investigated upon transfection in different cell lines, yet with inconclusive results. Although agonist binding properties were found to be unchanged for both variants, the impact on downstream signaling effects (i.e., adenylyl cyclase activation and cAMP formation) differed in the various cell lines studied (that also exhibited greatly varying receptor densities) (Table  21) . Studies investigating the function of endogenously expressed b 3 -adrenoceptor variants in adipocytes must be interpreted with some caution, because most of the agonists used are not specific for the b 3 -subtype and may act through ADRB1 and ADRB2. These studies are likewise contradictory, with some, but not all, suggesting hypofunctionality of the Arg64 variant with regard to agonist-induced lipolysis (Table 21) .
p.Trp46Arg is in linkage to several noncoding variants in the ADRB3 intronic region or 39-UTRs and 39-downstream regions (Hoffstedt et al., 1999; Teitsma et al., 2013) . These "haplotype blocks" have not been studied in detail to date, but are suggested to contribute to the phenotypic effects reported in vivo through a potential effect on receptor expression.
A larger study in a Chinese cohort recently reported that two frequent variants within the b 3 -adrenoceptor (p.Ser165Pro and p.Ser257Pro) are both associated with type 2 diabetes (see below) (Huang et al., 2013a) . Neither of these variants was previously found in other ethnicities. Position 165 is located in helix 4, where an amino acid change to proline may reasonably be expected to impair receptor structure and function. Serine at position 257 lies within the third intracellular loop and represents a putative phosphorylation site, which would be lost in the Pro257 variant. Both the Pro165 and Pro257 variants showed less agonist-induced cAMP formation after overexpression in two different cell lines, whereas phosphorylation of MAPK was retained (Table 21) .
Finally, the very rare variant c.794C.T (p.Thr265Met), located in intracellular loop 3 in the ADRB3 protein (Fig. 10B) , was functionally studied in vitro. No differences were reported with regard to ligand binding affinity and agonist-induced cAMP formation upon overexpression of the Thr265 and Met265 variants in HEK-293 cells (Table 21) . Adrenoceptor Polymorphic Variants
B. Role in Human Physiology and Disease
Because of its role in fat and muscle, the most common b 3 -adrenoceptor variation, p.Trp64Arg, has most intensely been investigated with regard to a potential role in metabolic abnormalities. Arg64 carriers showed a lower resting metabolic rate, an increased risk for obesity and insulin resistance, and a lower age of onset of noninsulin-dependent diabetes mellitus compared with Trp64 carriers in early studies (Clément et al., 1995; Kadowaki et al., 1995; Walston et al., 1995; Widén et al., 1995) . Although not all studies confirmed an association of Arg64 with metabolic disorders (Table 22) , a meta-analysis of .100 studies including .44,000 individuals showed an ethnicity-dependent susceptibility of the Arg64 allele for weight gain (determined as body mass index), as it was significantly associated with obesity specifically in Asians (Kurokawa et al., 2008) . Furthermore, four studies investigated an association of the p.Trp64Arg variant with the risk of hyperuricemia or gout and found this to be significant (Table 22 ). The smooth muscle relaxing properties of b 3 -adrenoceptors stimulation led to a large study (.1000 individuals) that tested for association of the p.Trp64Arg variation with bladder function in the context of benign prostate hyperplasia, but no significant differences among genotypes were reported (Teitsma et al., 2013) .
Candidate gene studies investigating an association of p.Trp64Arg with cardiac disease reported inconsistent results (Table 22) . With regard to the risk of type 2 diabetes, the largest study (including 7606 Danish individuals) reported an association of p.Trp64Arg 626 (Gjesing et al., 2008) . In addition, in a Chinese cohort including 650 patients with type 2 diabetes and 1337 healthy controls, the variations p.Ser165Pro and p.Ser257Pro were associated with susceptibility to type 2 diabetes and disease development (Huang et al., 2013a) . The latter findings of an association of b 3 -adrenoceptor variation with type 2 diabetes require further analysis, because the currently available GWAS results do not support an association of the ADRB3 locus with obesityor metabolism-related phenotypes (including type 2 diabetes; Table 4 ). This might suggest that neither p.Trp46Arg nor p.Ser165Pro and p.Ser257Pro are associated with disease.
VIII. Summary and Conclusions
Adrenoceptors execute activation of the sympathetic nervous system on the cellular level. As such, they are key molecules to determine multiple organ functions in health and disease and are targets of widely used therapeutic drugs. All nine adrenoceptor genes display genetic variation, including nonsynonymous variations in their coding regions. This variation has fueled speculations about their possible functional relevance and has consequently been the basis of a multitude of studies on adrenoceptor variation. As a result, ADRB1 and ADRB2 range among the most frequently studied genes with regard to a potential involvement of their genetic variation in human physiology, disease, or drug response. Despite the enormous effort invested in these studies, hard evidence for a significant impact of adrenoceptor variation on any parameter related to adrenoceptor function remains disappointingly scarce and refers to a very small number of variants (for details, see the summaries at the end of Sections III-VII). What are the likely reasons underlying this overt discrepancy? A number of early and exciting candidate gene studies (i.e., studies that specifically investigate variations in a selected gene, as opposed to a genomewide approach) originally reported on associations of adrenoceptor variation and human disease. Unfortunately, the restriction to a specific candidate gene made these studies vulnerable to undetected bias and false positive results. Although many studies had been conducted, some reports typically confirmed such Tables 15-17 and  22 ). The larger the numbers of individuals included in a study (listed toward the bottom of Tables 15-17 and 22), the less likely such an association was often reported.
The recent broad application of genome-wide association undoubtedly led to a change of human genetics in a paradigmatic way (Katsanis and Katsanis, 2013) and also changed our appreciation of previously reported candidate gene-centered association studies. We must acknowledge that previously accepted standards for the reporting of genetic associations have apparently not been rigorous enough to prevent false interpretations. The problematic validity of candidate gene studies raises the question of whether they can be expected to contribute meaningful results to our understanding of adrenoceptor variation.
With the recent formation of very large consortia (i.e. .10,000 subjects), we can expect an even higher sensitivity to detect genetic determinants of specific traits in the future. For candidate gene studies, we envision a less prominent role in very defined and less complex settings, such as the testing of acute drug responses in primary human cells or humans (see below).
GWAS have become the gold standard to associate a variation with a certain trait, but the number of such studies is currently too low to draw a comprehensive picture on the role of adrenoceptor variation. Only two of the nine adrenoceptor subtypes appear in GWAS. For the ADRA2A gene, variations in the 39-downstream region were found to be associated with fasting glucoserelated traits and epinephrine-induced platelet aggregation. Variations in the ADRB1 gene identified in the 59-upstream region and in the coding region were associated with blood pressure and birth weight, respectively. The latter represents the most common variation in the b 1 -adrenoceptor, c.1165C.G (p.Arg389Gly), and is the only variation within the coding region of an adrenoceptor that yielded a GWAS "hit" (i.e., a significant association with a predefined trait).
Aside from weighing the pros and cons of genecentered studies versus GWAS, there is also a need to discuss the apparent ambiguity of some of the studies that analyzed adrenoceptor variation in vitro. Typically, the functional and biochemical consequences of Li et al. (1996) Visceral adipocytes Tables 2 and  21 ). Such discrepancies might be due to ligand-dependent selectivity for certain signaling pathways ("biased agonism"; Evans et al., 2010) and cell line-specific equipment with G proteins, other receptor interacting proteins and signal pathway components as well as abnormal G protein coupling caused by high-level overexpression of receptors. All of these factors can potentially determine certain downstream effects, agonist-promoted receptor phosphorylation, and receptor desensitization. Future studies in vitro on adrenoceptor variation will benefit from more rigorously controlled cellular systems, such as better defined "knock-in" cell lines , which permit the head-to-head comparison of receptor variants expressed from the same genetic locus in a defined copy number. Most available data on the drug response of adrenoceptor variants suffer similar limitations as candidate gene studies do for disease association (i.e., heterogeneity and limited size of the study population). In this regard, the appreciation of the functional impact of the p.Arg389Gly variation in the b 1 -adrenoceptor appears as most unequivocal. The presence of a glycine at position 389 in the b 1 -adrenoceptor [c.1165C.G (p.Arg389Gly)] has repeatedly been observed in large clinical trials to reduce the efficacy of treatment with b-blockers. Cardiac and blood pressure responses to b-blocker treatment were significantly stronger in Arg389-b 1 -adrenoceptor homozygotes than in subjects carrying one or two alleles of the Gly389-b 1 -adrenoceptor in patients with essential hypertension and chronic heart failure. While not supported by hard evidence from clinical studies to date, the prospective determination of adrenoceptor genotypes may aid to personalize patient treatment with several drugs currently prescribed. For example, by assessing the b 1 -adrenoceptor genotype of a patient, the responsiveness to b 1 -agonists or b 1 -antagonists could be predicted (Arg389, good responders; Gly389, poor responders) and the dose of the drug might be adopted depending on the genotype (Gly389, higher dose). Other adrenoceptor variants did not show a consistent correlation with drug response, yet they have been comparably less intensely studied, with room for improvement. Ultimately, we may expect that GWAS on drug response will help to elucidate which adrenoceptor variations determine drug response and which do not. Zafarmand et al. (2008) BMI, body mass index; BP, blood pressure; CAD, coronary artery disease; CHD, coronary heart disease; GDM, gestational diabetes mellitus; HT, hypertensive; IHD, ischemic heart disease; NIDDM, noninsulin-dependent diabetes mellitus; NT, normotensive; OAB, overactive bladder; T2D, type 2 diabetes. 630 Ahles and Engelhardt 
